title: Improved rat steatotic and nonsteatotic liver preservation by the addition of epidermal growth factor and insulin-like growth factor-I to University of Wisconsin solution.
abstract: This study examined the effects of epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I) supplementation to University of Wisconsin solution (UW) in steatotic and nonsteatotic livers during cold storage. Hepatic injury and function were evaluated in livers preserved for 24 hours at 4 degrees C in UW and in UW with EGF and IGF-I (separately or in combination) and then perfused ex vivo for 2 hours at 37 degrees C. AKT was inhibited pharmacologically. In addition, hepatic injury and survival were evaluated in recipients who underwent transplantation with steatotic and nonsteatotic livers preserved for 6 hours in UW and UW with EGF and IGF-I (separately or in combination). The results, based on isolated perfused liver, indicated that the addition of EGF and IGF-I (separately or in combination) to UW reduced hepatic injury and improved function in both liver types. A combination of EGF and IGF-I resulted in hepatic injury and function parameters in both liver types similar to those obtained by EGF and IGF-I separately. EGF increased IGF-I, and both additives up-regulated AKT in both liver types. This was associated with glycogen synthase kinase-3beta (GSK3(beta)) inhibition in nonsteatotic livers and PPAR gamma overexpression in steatotic livers. When AKT was inhibited, the effects of EGF and IGF-I on GSK3(beta), PPAR gamma, hepatic injury and function disappeared. The benefits of EGF and IGF-I as additives in UW solution were also clearly seen in the liver transplantation model, because the presence of EGF and IGF-I (separately or in combination) in UW solution reduced hepatic injury and improved survival in recipients who underwent transplantation with steatotic and nonsteatotic liver grafts. In conclusion, EGF and IGF-I may constitute new additives to UW solution in steatotic and nonsteatotic liver preservation, whereas a combination of both seems unnecessary.
authors.affiliation: Experimental Hepatic Ischemia-Reperfusion Unit, Institut d'Investigacions Biomèdiques de Barcelona-Consejo Superior de Investigaciones Científicas, Barcelona, Spain.
authors.forename: M Amine
authors.initials: MA
authors.lastname: Zaouali
authors.forename: Susagna
authors.initials: S
authors.lastname: Padrissa-Altés
authors.forename: Ismail
authors.initials: I
authors.lastname: Ben Mosbah
authors.forename: Izabel
authors.initials: I
authors.lastname: Alfany-Fernandez
authors.forename: Marta
authors.initials: M
authors.lastname: Massip-Salcedo
authors.forename: Araní
authors.initials: A
authors.lastname: Casillas-Ramirez
authors.forename: María
authors.initials: M
authors.lastname: Bintanel-Morcillo
authors.forename: Olivier
authors.initials: O
authors.lastname: Boillot
authors.forename: Anna
authors.initials: A
authors.lastname: Serafin
authors.forename: Antoni
authors.initials: A
authors.lastname: Rimola
authors.forename: Juan
authors.initials: J
authors.lastname: Rodés
authors.forename: Joan
authors.initials: J
authors.lastname: Roselló-Catafau
authors.forename: Carmen
authors.initials: C
authors.lastname: Peralta
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D002470:Cell Survival; D050377:Cold Ischemia; D004195:Disease Models, Animal; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005234:Fatty Liver / Q000473:pathology / Q000601:surgery*; D005978:Glutathione / Q000494:pharmacology; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D007328:Insulin / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D047495:PPAR gamma / Q000378:metabolism; D010477:Perfusion; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism; D011887:Raffinose / Q000494:pharmacology; D051381:Rats; D011924:Rats, Zucker; D011994:Recombinant Proteins / Q000494:pharmacology; D015427:Reperfusion Injury / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D007328:Insulin; D019188:Organ Preservation Solutions; D047495:PPAR gamma; D047428:Protein Kinase Inhibitors; D011994:Recombinant Proteins; C055206:University of Wisconsin-lactobionate solution; D004815:Epidermal Growth Factor; D000493:Allopurinol; D007334:Insulin-Like Growth Factor I; D000071679:Glycogen Synthase Kinase 3 beta; C000605508:Gsk3b protein, rat; D051057:Proto-Oncogene Proteins c-akt; D038362:Glycogen Synthase Kinase 3; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose